Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00314444 · ClinicalTrials.gov registry record

Treatment for Psychogenic Disorders

A clinical trial, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

Completed
Registry status
15
Enrollment target

NCT00314444: Completed study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

NCT00314444 is a clinical trial that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00314444 has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

COMPLETED
Registry status
15 participants
Enrollment target

Study Summary

This study will examine whether biofeedback treatment is effective in lessening or stopping movement symptoms in people with psychogenic movement disorder. People with this condition have increased or decreased movements that are not under their control and are not associated with any know problem with the nervous system. Biofeedback is a type of therapy that uses electronic instruments to monitor breathing and heart rate. This treatment has been effective in patients with anxiety and panic attacks. People 18 years of age and older diagnosed with psychogenic movement disorder may be eligible for this study. Candidates are screened with a neurological history, physical examination and psychiatric evaluation. Participants come to the NIH Clinical Center for nine 1-hour test sessions over an 8-week period for the following procedures: Week 1 (two visits): * Patients' movements are videotaped while they sit, stand and walk. * Patients train on RESPeRATE device, a computerized musical biofeedback device to help slow theirs breathing rate. The device has three components: a computerized module, earphones, and a chest strap holding a breath sensor. The patients put the elastic strap around their chest, put on the earphones, and sit in a chair. The device monitors and analyzes their breathing to create a melody composed of two distinct tones - one for inhalation and one for exhalation. Patients are instructed to match their breathing to the tones, which gradually slow until they are breathing at a slower, therapeutic rate. * Patients' breathing is monitored and analyzed for information on breathing pattern and rate. * Patients complete questionnaires on level of relaxation before and after RESPeRATE training. * Patients take the RESPeRATE device home to use for two 10-minute practice sessions per day. They complete relaxation questionnaires before and after each session. Weeks 2-7: * Patients' progress is monitored and reviewed from the previous week * Patients' breat

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2006-04-07
Est. Completion 2009-04-14

What the finished NCT00314444 record still lists

NCT00314444 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00314444 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00314444 about?

NCT00314444 is a clinical study titled "Treatment for Psychogenic Disorders". This study will examine whether biofeedback treatment is effective in lessening or stopping movement symptoms in people with psychogenic movement disorder. People with this condition have increased or decreased movements that are not under their control and are not associated with any know problem w...

What is the current status of trial NCT00314444?

This trial is currently completed. The enrollment target is 15 participants. The study started on 2006-04-07. Estimated completion is 2009-04-14.

Who is sponsoring clinical trial NCT00314444?

This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00314444, the US trial registry maintained by the National Library of Medicine. NCT00314444 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.